naa a22 4500 510763189 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12094-012-0883-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0883-2 Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM [Elektronische Daten] [Alka Madaan, Pratibha Singh, Anshumali Awasthi, Ritu Verma, Anu Singh, Manu Jaggi, Shiva Mishra, Sadanand Kulkarni, Hrishikesh Kulkarni] Introduction: An increasing research interest has been directed toward nanoparticle-based drug delivery systems for their advantages. The appropriate amalgamation of pH sensitivity and tumor targeting is a promising strategy to fabricate drug delivery systems with high efficiency, high selectivity and low toxicity. Materials and Methods: A novel pH sensitive Cremophor-free paclitaxel formulation, NanoxelTM, was developed in which the drug is delivered as nanomicelles using a polymeric carrier that specifically targets tumors. The efficiency and mechanism of intracellular paclitaxel delivery by NanoxelTM was compared with two other commercially available paclitaxel formulations: AbraxaneTM and IntaxelTM, using different cell lines representing target cancers [breast, ovary and non-small cell lung carcinoma (NSCLC)] by transmission electron microscopy and quantitative intracellular paclitaxel measurements by high performance liquid chromatography. Results: The data obtained from the present study revealed that the uptake of nanoparticle-based formulations NanoxelTM and AbraxaneTM is mediated by the process of endocytosis and the uptake of paclitaxel was remarkably superior to IntaxelTM in all cell lines tested. Moreover, the intracellular uptake of paclitaxel in NanoxelTM- and AbraxaneTM-treated groups was comparable. Hence, the nanoparticle-based formulations of paclitaxel (NanoxelTM and AbraxaneTM) are endowed with higher efficiency to deliver the drug to target cells as compared to the conventional Cremophor-based formulation. Conclusion: NanoxelTM appears to be of great promise in tumor targeting and may provide an advantage for paclitaxel delivery into cancer cells. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Paclitaxel nationallicence Delivery system nationallicence Tumor nationallicence Naoxel nationallicence Nanoparticle nationallicence Intaxel nationallicence Madaan Alka Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut Singh Pratibha Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut Awasthi Anshumali Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut Verma Ritu Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut Singh Anu Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut Jaggi Manu Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut Mishra Shiva Medical Affairs and Clinical Research, Fresenius Kabi India Private Limited, Echelon Institutional Area, Plot No 11, Sector 32, 121001, Gurgaon, Haryana, India aut Kulkarni Sadanand Medical Affairs and Clinical Research, Fresenius Kabi India Private Limited, Echelon Institutional Area, Plot No 11, Sector 32, 121001, Gurgaon, Haryana, India aut Kulkarni Hrishikesh Fresenius Kabi Asia Pacific Limited, 50/F Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong aut Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 26-32 1699-048X 15:1<26 2013 15 12094 https://doi.org/10.1007/s12094-012-0883-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0883-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Madaan Alka Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut NATIONALLICENCE 700 1- Singh Pratibha Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut NATIONALLICENCE 700 1- Awasthi Anshumali Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut NATIONALLICENCE 700 1- Verma Ritu Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut NATIONALLICENCE 700 1- Singh Anu Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut NATIONALLICENCE 700 1- Jaggi Manu Dabur Research Foundations, 22, Site IV, Sahibabad, 201010, Ghaziabad, Uttar Pradesh, India aut NATIONALLICENCE 700 1- Mishra Shiva Medical Affairs and Clinical Research, Fresenius Kabi India Private Limited, Echelon Institutional Area, Plot No 11, Sector 32, 121001, Gurgaon, Haryana, India aut NATIONALLICENCE 700 1- Kulkarni Sadanand Medical Affairs and Clinical Research, Fresenius Kabi India Private Limited, Echelon Institutional Area, Plot No 11, Sector 32, 121001, Gurgaon, Haryana, India aut NATIONALLICENCE 700 1- Kulkarni Hrishikesh Fresenius Kabi Asia Pacific Limited, 50/F Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 26-32 1699-048X 15:1<26 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer